期刊文献+

闽东地区畲族人群CYP2C19基因多态性分析 被引量:4

Analysis of CYP2C19 gene polymorphism of the She nationality in eastern Fujian Province
下载PDF
导出
摘要 目的:调查闽东地区汉族与畲族人群CYP2C19基因多态性分布情况。方法:采用限制性片段长度多态性聚合酶链反应(PCR-RFLP),对汉族(n=140)与畲族(n=180)人群CYP2C19两个多态性位点CYP2C19*2和CYP2C19*3的基因多态性进行分析,用SPSS16.0软件进行统计分析,Hardy-Weinberg遗传平衡定律验证基因型分布情况。结果:汉族与畲族人群各种基因型出现频率分别为:*1/*1 14.3%,28.9%;*1/*2 28.6%,30.0%;*1/*3 11.4%,16.7%;*2/*2 21.4%,9.4%;*2/*3 21.4%,12.8%;*3/*3 2.9%,2.2%。汉族与畲族CYP2C19不同等位基因出现频率:*1为34.3%,52.2%;*2为46.4%,30.8%;*3为19.3%,16.9%。结论:闽东地区畲族与汉族CYP2C19*2与*3等位基因突变率存在差异,畲族人群基因突变率低于汉族(P<0.05)。 Objective: To investigate the distribution of CYP2C19 gene polymorphism of the Han and the She nationalities in eastern Fujian Province. Methods Detection of cYPgC19 · 2 and CYP2C19·3 mutant alleles of the Han(n=140) and the She(n= 180) nationalities was performed using polymerase chain reaction-restriction fragment length polymorphism method. The data were analyzed by SPSS16.0 software. CYP2C19 genotype frequencies of the Han and the She nationalities in eastern Fujian Province were verified by Hardy-Weinberg equilibrium. Resuits:CYP2C19 genotype frequencies of the Han and the She nationalitieswere·l/·1 14.3%,28.9%· 1/· 2 28. 6%,30.0·/0· 1/· 3 11. 4%,16. 7%· 2/· 2 21. 4%,9. 4%;· 2/· 3 21.4%, 12.8% ; · 3/· 3 2.9% ,2.2% ,respectively. The mutant alleles frequencies of CYP2C19 of the Han and the She national- ities were, · 1 34.3%,52.2%· 2 46.4%,30.8%;· 3 19.3%,16.9% ,respectively. Conclusion:The mutant alleles frequencies of CYP2C19· 2 and CYP2C19· 3 of the She nationality were significantly lower than those of the Han nationality(P〈0.05).
出处 《药学服务与研究》 CAS CSCD 2014年第5期364-367,共4页 Pharmaceutical Care and Research
基金 福建省宁德市科技计划项目(20120070)
关键词 CYP2C19 基因多态性 畲族 限制性片段长度多态性聚合酶链反应 等位基因突变频率 CYP2C19 gene polymorphism She nationality polymerase chain reaction-restriction fragment length polymorphism mutant alleles frequencies
  • 相关文献

参考文献12

  • 1Nguyen T A,Diodati J G,Pharand C.Resistance to clopidogrel:a review of the evidence[J].J Am Coll Cardiol,2005,45(8):1157-1164.
  • 2Lordkipanidzé M,Pharand C,Palisaitis D A,et al.Aspirin resistance:truth or dare[J].Pharmacol Ther,2006,112(3):733-743.
  • 3Tantry U S,Bliden K P,Wei C,et al.First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel:the ONSET/OFFSET and RESPOND genotype studies[J].Circ Cardiovasc Genet,2010,3(6):556-566.
  • 4Zand N,Tajik N,Hoormand M,et al.Allele frequency of CYP2C19 gene polymorphisms in a healthy Iranian population[J].Iranian J Pharmacol Ther,2005,4(2):124-127.
  • 5Subraja K,Dkhar S A,Priyadharsini R,et al.Genetic polymorphisms of CYP2C19 influence the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population[J].Eur J Clin Pharmacol,2013,69(3):415-422.
  • 6US Food and Drug Administration.FDA drug safety communication:reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug[EB/OL].(2010-12-13)[2013-10-01].http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ ucm203888.htm.
  • 7Ozawa S,Soyama A,Saeki M,et al.Ethnic differences in genetic polymorphisms of CYP2D6,CYP2C19,CYP3As and MDR1/ABCB1[J].Drug Metab Pharmacokinet,2004,19(2):83-95.
  • 8Goldstein J A,Ishizaki T,Chiba K,et al.Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental,Caucasian,Saudi Arabian and American black populations[J].Pharmacogenetics,1997,7(1):59-64.
  • 9Shu Yan,Zhou HongHao.Individual and ethnic differences in CYP2C19 activity in Chinese populations[J].Acta Pharmacol Sin,2000,21(3):193-199.
  • 10闫春兰,詹金彪,陈枢青.浙江省汉族与畲族CYP2C19基因多态性研究[J].中国药学杂志,2004,39(11):866-868. 被引量:13

二级参考文献4

  • 1He N, Yan FX, Huang SL. CYP2C19 genotype and S-mephenytoin4 '-hydroxylation phenotype in a Chinese Dai population[J]. Eur J Clin Pharmacol , 2002,58:15.
  • 2Yan S, Zhou HH. Individual and ethnic differences in CYP2C19 activity in Chinese population [J]. Acta Pharmacol Sin, 2000,21 (3): 193.
  • 3Zhou SX, Goldstein JA, Xie HG. Differences in the incidence of the CYP2C19 polymorphism affecting the S-Mephenytoin phenotype in Chinese han and bai population and identification of a new rare CYP2C19 Mutant Allele [J]. J Pharmacol Exp Ther , 1997, 28 (1)
  • 4Karen L. Furie,Scott E. Kasner,Robert J. Adams,Gregory W. Albers,Ruth L. Bush,Susan C. Fagan,Jonathan L. Halperin,S. Claiborne Johnston,Irene Katzan,Walter N. Kernan,Pamela H. Mitchell,Bruce Ovbiagele,Yuko Y. Palesch,Ralph L. Sacco,Lee H. Schwamm,Sylvia Wassertheil-Smoller,Tanya N. Turan,Deidre Wentworth,李海峰(译),刘涛(译),杨潘(译),王鹏(译).卒中或短暂性脑缺血发作患者的卒中预防指南 美国心脏协会/美国卒中协会为医疗卫生专业人员制定的指南[J].国际脑血管病杂志,2011,19(1):1-49. 被引量:392

共引文献36

同被引文献45

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部